Life Sciences Catalyst beyond border
Patrice Rool created Roowin in 1998 and became CEO. Very creative in chemistry, he is the inventor of Roowin’s patents.
Roowin, a company specialized in high added value fine chemistry, can support you in your projects of creation, implementation, optimization and scale-up of efficient synthesis-routes and analysis methods.
Roowin’s team is at your service for any chemistry research projects you want to entrust to us. In November 2009, Roowin employed 35 chemists. Our management team with a PhD/Grande Ecole rate of 100% is looking forward to all challenges you might want to share with us.
To learn more about Roowin: http://www.roowin.com/
Based in San Francisco, CA, Ennov makes the most cost effective, comprehensive, and user-friendly solutions for regulated content management.
They are proud to serve over 500 customers with a total of 250,000 users, ranging from leading pharmaceutical companies to emerging biotechnology companies throughout the life sciences industry.
With over 15 years of experience and active feedback from customers, the Ennov team has fine-turned an all-in-one platform for faster deployment to market and continuous quality assurance. With the added efficiency of Ennov’s applications, their customers can accomodate their growing workload without nedding additiona resources.
To learn more about Ennov: http://www.ennov.com/us/
Integrium Clinical Research specializes in the strategy, study design, and execution of Phase I-IV clinical trials, with an expertise in Proof of Concept trials.
It has strong clinical trial experience in a range of therapeutic indications including cardiovascular, metabolic, renal, inflammatory, dermatology, regenerative, orphan, and wound healing drug development. Founded in 1998, Integrium has 100+ employees with CRO, PK Unit, and Research Clinic locations in California, New Jersey, and South Africa. It has access to 7,000+ patients within varying disease states and 2,500+ healthy volunteers. It has also CRO partners in Europe, Australia, and India. The PK Unit is equipped with the necessary tools to run your Phase I POC study and the unparalleled Patient Recruitment team will assure your patient enrollment success.
Please contact Randa Wahid for more details: Randa.Wahid@integrium.com
Paul Herzog practices immigration law with a focus on high-tech companies, universities, research institutes and small businesses/start ups. He earned his J.D. from Tulane University Law School and is member of the American Immigration Lawyers Association (AILA) and the Los Angeles County Bar Association-Immigration Section. Paul has written articles about immigration law, as well as lectured on immigration at schools and conferences. He currently serves as co-chair of the AILA Southern California LAX Customs & Border Patrol Liaison Group.
Phuong Nguyen is the founder and President of Odexxo Inc., and the mind behind the design of the company’s patented technology. Phuong joined the Life Science field in the early 2000s, after a decade of experience in investment banking in Monaco. She held sales and marketing positions at Thermo, Acon Labs and Alfa Scientific, and was responsible for developing European distribution channels for in-vitro diagnostic products.
Phuong graduated with a business degree from the Ecole Superieure de Commerce in Clermont-Ferrand, France and an MBA from the University of San Diego. She is trilingual English-French-Vietnamese, and has a good knowledge of Italian and German.
ODEXXO Inc. specializes in the design, development and marketing of proprietary disposable devices for in-
vitro diagnostic applications.
ODEXXO’s products enable simple and clean handling of multiplex immuno-chromatographic rapid tests, offering physicians and veterinarians a very convenient point-of-care and field diagnostic tool. Launched in 2010, the technology has since been widely used by global veterinary IVD and pharmaceutical companies.
In partnership with BIO-X, a Belgian veterinary diagnostic manufacturer, ODEXXO is launching the first complete porcine rapid test panel for the simultaneous detection of 8 pathogens that cause digestive diseases.
Dr. Richard Lin is the Founder and CEO of Explora BioLabs, a San Diego based preclinical pharmacology contract research company. With over 20 years of academic research and biotech drug development experience, Richard brought his substantial scientific background to the research service industry. Prior to founding Explora BioLabs, Richard served as a Research Investigator at Ansata Therapeutics. He headed the group responsible for the preclinical development of Ansata’s novel antimicrobial peptides in support of their advancement toward IND filing. Richard also served as head of the Physiology Department at Genset Corporation, where he led the effort to determine the in vivo functions of Genset’s leading therapeutic proteins in the areas of obesity and diabetes. Richard’s earlier biotech experience included a Group Leader position at Corvas International, and a Senior Scientist position at Axys Pharmaceuticals. Richard conducted his postdoctoral research at UC San Diego Cancer Center, and received his PhD in Zoology from UC Berkeley.
Explora BioLabs is a San Diego based preclinical pharmacology contract research company that provides custom-tailored discovery pharmacology services focusing on PK, non-GLP toxicology, oncology, infectious and metabolic diseases, wound healing and novel model development. The company delivers professionally-managed, cost-effective, premium vivarium services, enabling pharma, biotech and leading academic researchers to accelerate their preclinical programs by virtualizing their pharmacology infrastructure.